Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors

Inhibitor screening is an important tool for drug development, especially during the COVID-19 pandemic. The most used in vitro inhibitor screening tool is an enzyme-linked immunosorbent assay (ELISA). However, ELISA-based inhibitor screening is time consuming and has a limited dynamic range. Using f...

Full description

Bibliographic Details
Main Authors: Shira Roth, Amos Danielli
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Sensors
Subjects:
Online Access:https://www.mdpi.com/1424-8220/21/14/4814
id doaj-40fa4410d8ef4dd5a5d113c960266034
record_format Article
spelling doaj-40fa4410d8ef4dd5a5d113c9602660342021-07-23T14:05:51ZengMDPI AGSensors1424-82202021-07-01214814481410.3390/s21144814Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated BiosensorsShira Roth0Amos Danielli1Faculty of Engineering, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Max and Anna Webb Street, Ramat Gan 5290002, IsraelFaculty of Engineering, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Max and Anna Webb Street, Ramat Gan 5290002, IsraelInhibitor screening is an important tool for drug development, especially during the COVID-19 pandemic. The most used in vitro inhibitor screening tool is an enzyme-linked immunosorbent assay (ELISA). However, ELISA-based inhibitor screening is time consuming and has a limited dynamic range. Using fluorescently and magnetically modulated biosensors (MMB), we developed a rapid and sensitive inhibitor screening tool. This study demonstrates its performance by screening small molecules and neutralizing antibodies as potential inhibitors of the interaction between the spike protein 1 (S1) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the angiotensin-converting enzyme 2 (ACE2) receptor. The MMB-based assay is highly sensitive, has minimal non-specific binding, and is much faster than the commonly used ELISA (2 h vs. 7–24 h). We anticipate that our method will lead to a remarkable advance in screening for new drug candidates.https://www.mdpi.com/1424-8220/21/14/4814magnetically aggregated biosensorsinhibitor screeningSARS-CoV-2spike proteinangiotensin-converting enzyme 2neutralizing antibodies
collection DOAJ
language English
format Article
sources DOAJ
author Shira Roth
Amos Danielli
spellingShingle Shira Roth
Amos Danielli
Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors
Sensors
magnetically aggregated biosensors
inhibitor screening
SARS-CoV-2
spike protein
angiotensin-converting enzyme 2
neutralizing antibodies
author_facet Shira Roth
Amos Danielli
author_sort Shira Roth
title Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors
title_short Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors
title_full Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors
title_fullStr Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors
title_full_unstemmed Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors
title_sort rapid and sensitive inhibitor screening using magnetically modulated biosensors
publisher MDPI AG
series Sensors
issn 1424-8220
publishDate 2021-07-01
description Inhibitor screening is an important tool for drug development, especially during the COVID-19 pandemic. The most used in vitro inhibitor screening tool is an enzyme-linked immunosorbent assay (ELISA). However, ELISA-based inhibitor screening is time consuming and has a limited dynamic range. Using fluorescently and magnetically modulated biosensors (MMB), we developed a rapid and sensitive inhibitor screening tool. This study demonstrates its performance by screening small molecules and neutralizing antibodies as potential inhibitors of the interaction between the spike protein 1 (S1) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the angiotensin-converting enzyme 2 (ACE2) receptor. The MMB-based assay is highly sensitive, has minimal non-specific binding, and is much faster than the commonly used ELISA (2 h vs. 7–24 h). We anticipate that our method will lead to a remarkable advance in screening for new drug candidates.
topic magnetically aggregated biosensors
inhibitor screening
SARS-CoV-2
spike protein
angiotensin-converting enzyme 2
neutralizing antibodies
url https://www.mdpi.com/1424-8220/21/14/4814
work_keys_str_mv AT shiraroth rapidandsensitiveinhibitorscreeningusingmagneticallymodulatedbiosensors
AT amosdanielli rapidandsensitiveinhibitorscreeningusingmagneticallymodulatedbiosensors
_version_ 1721285968900653056